Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Cohen, Pinhas / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Roth, Christian / Toppari, Jorma

Editorial Board Member: Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / Hiort, Olaf / LaFranchi, Stephen H. / Lanes M. D., Roberto / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Zadik, Zvi


IMPACT FACTOR 2015: 0.912

SCImago Journal Rank (SJR) 2015: 0.493
Source Normalized Impact per Paper (SNIP) 2015: 0.600
Impact per Publication (IPP) 2015: 0.955

149,00 € / $224.00 / £112.00*

Online
ISSN
2191-0251
See all formats and pricing

 


Select Volume and Issue

Issues

Temperature-responsive and biodegradable PVA:PVP k30:poloxamer 407 hydrogel for controlled delivery of human growth hormone (hGH)

Azade Taheri1 / Fatemeh Atyabi1 / 1, 2

1Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medicinal Science, Tehran, Iran

2Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Corresponding author: Rassoul Dinarvand, PhD, Professor of Pharmaceutics, Dean, Faculty of Pharmacy, Tehran University of Medical Sciences, PO Box 14155-6451, Tehran, Iran Phone: +98-21-66959095, Fax: +98-21-66959096

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 24, Issue 3-4, Pages 175–179, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem.2011.079, April 2011

Publication History

Published Online:
2011-04-14

Abstract

Recombinant human growth hormone (rhGH) is used for replacement therapy of pediatric hypopituitary dwarfism. Growth rate in children was observed to be better on the daily injection schedule compared with the currently used therapeutic regimen of thrice a week injection. Thus, a controlled release formulation would overcome the drawback of traditional rhGH therapy such as the need for multiple injections. Poloxamers are a family of triblock copolymers consisting of two hydrophilic blocks of polyoxyethylene separated by a hydrophobic block of polyoxypropylene, which form micelles at low concentrations and form clear thermally reversible gels at high concentrations. We used poloxamer gels to develop a controlled release formulation of hGH. The objective of this study was to develop an in situ gel forming drug delivery system for hGH using the minimum possible ratio of poloxamer 407 (P407). Decreasing the concentration of poloxamer could reduce the risk of hypertriglyceridemia induction. Different additives were added to the poloxamer formulations. It was observed that among different additives polyvinylpyrrolidone k30 (PVP k30) and polyvinyl alcohol (PVA) decrease poloxamer concentration required to form in situ gelation from 18% to 10%. The dynamic viscoelastic properties of the samples were determined. Both the storage modulus and the loss modulus of the samples increased abruptly as the temperature passed a certain point. It can be concluded that combining P407 and PVP and PVA could be a promising strategy for preparation of thermally reversible in situ gel forming delivery systems of hGH with low poloxamer concentration.

Keywords: block copolymers; gelation; gels; human growth hormone (hGH); in situ gel forming systems; poloxamer 407; polyvinyl alcohol (PVA); polyvinylpyrrolidone (PVP); rheology; stimuli-sensitive polymers

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Diana Arbealez-Camargo, Josep Maria Suñé-Negre, Manel Roig-Carreras, Encarna García-Montoya, Pilar Pérez-Lozano, Montserrat Miñarro-Carmona, and Josep Ramon Ticó-Grau
International Journal of Pharmaceutics, 2015
[2]
Jong Seo Choi, Dong Wuk Kim, Dong Shik Kim, Jong Oh Kim, Chul Soon Yong, Kwan Hyung Cho, Yu Seok Youn, Sung Giu Jin, and Han-Gon Choi
Drug Delivery, 2015, Page 1
[3]
Orapin V. Horst, Miquella G. Chavez, Andrew H. Jheon, Tejal Desai, and Ophir D. Klein
Dental Clinics of North America, 2012, Volume 56, Number 3, Page 495
[4]
Sh. Abashzadeh, R. Dinarvand, M. Sharifzadeh, G. Hassanzadeh, M. Amini, and F. Atyabi
European Journal of Pharmaceutical Sciences, 2011, Volume 44, Number 4, Page 514

Comments (0)

Please log in or register to comment.